Alnylam Pharmaceuticals Inc., a Cambridge company looking to develop therapeutics based on RNA interference, said it has restructured its relationship with Tekmira Pharmaceuticals with a new licensing agreement. It also said the companies have resolved all litigation between them. Tekmira will receive $65 million, and is eligible to receive $10 million in near-term milestone payments. The litigation involved intellectual property rights of lipid nanoparticle technology, Tekmira said.
Alnylam Pharmaceuticals settles legal battle
| Globe Staff November 18, 2012
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢